Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Adagene and Incyte form alliance to target treatment-resistant colorectal cancer

Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.

Leia mais: Adagene and Incyte form alliance to target treatment-resistant colorectal cancer
Grafa

AstraZeneca immunotherapy combo delays liver cancer progression in Phase III study

AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.

Leia mais: AstraZeneca immunotherapy combo delays liver cancer progression in Phase III study
Grafa

Merck accelerates EyeBio integration with pivotal trial for dual-action retina therapy

Merck (NYSE:MRK) has officially moved its lead ophthalmology candidate into late-stage development, initiating a pivotal Phase 2b/3 trial for MK-8748 just two years after the pharmaceutical giant’s $3 billion acquisition of EyeBio.

Leia mais: Merck accelerates EyeBio integration with pivotal trial for dual-action retina therapy
Grafa
Technology

Lindsay profits profits slump as demand eases across irrigation and Infrastructure

Lindsay (NYSE:LNN) reported a sharp decline in second-quarter profitability as a contraction in both its agricultural and infrastructure segments weighed on the top line, leading to a more than 50% drop in net earnings.

Leia mais: Lindsay profits profits slump as demand eases across irrigation and Infrastructure
Grafa
Oil and Gas

Transocean secures $1B in new deals as debt reduction strategy accelerates

Transocean (NYSE:RIG) has fortified its financial position through a dual-track strategy of aggressive backlog expansion and balance sheet deleveraging, announcing approximately $1 billion in new contract awards alongside the full retirement of a high-interest bond series.

Leia mais: Transocean secures $1B in new deals as debt reduction strategy accelerates